Latest Conference Coverage

Sustained Reductions of Brain Atrophy Observed With S1P Modulator Ozanimod

In the original phase 3 studies, treatment with ozanimod resulted in significant reductions in clinical relapses and lesion counts on MRI as well as slowed brain volume loss relative to intramuscular interferon-β-1a.

End-of-Dose Phenomena Observed With Multiple Sclerosis Medication Ofatumumab

Towards the end of ofatumumab dosing, administered monthly via subcutaneous injection, patients noted issues like fatigue, cognitive impairment, and gait difficulties.

Simvastatin Fails to Reduce Disease Progression in Phase 3 MS-STAT2 Trial of Secondary Progressive Multiple Sclerosis

A phase 3 trial revealed that simvastatin, while safe, did not significantly slow disability progression in patients with non-active secondary progressive MS.

Tolebrutinib Shows Positive Results in Slowing Disability Progression for Non-Relapsing Secondary Progressive MS in Phase 3 HERCULES Trial

In a phase 3 study, tolebrutinib demonstrated a statistically significant delay in time to onset of confirmed disability progression in patients living with non-relapsing secondary progressive multiple sclerosis.

Phase 3 MOGwAI Trial to Test Azathioprine as First-Line Treatment for MOGAD

The randomized phase 3 trial will test the hypothesis that the initiation of azathioprine after a first attack of MOGAD could prevent further relapse and disability accrual.

The Promising Results of Tolebrutinib for Secondary Progressive Multiple Sclerosis Treatment: Robert J. Fox, MD

The staff neurologist at the Mellen Center for Multiple Sclerosis at Cleveland Clinic talked about a promising therapy that slows the progression of disability in non-relapsing secondary progressive multiple sclerosis. [WATCH TIME: 2 minutes]

Tolebrutinib Slows Disability Worsening in GEMINI Trials of Relapsing MS, Despite Failing to Meet Primary End Point

The positive finding on the secondary end point of 6-month confirmed disability worsening supports the data from the phase 3 HERCULES trial in secondary progressive multiple sclerosis.

Comparative Analysis Insights on Neuromyelitis Optica Spectrum Disorder Treatments: Shamik Bhattacharyya, MD

The associate professor of neurology at Harvard Medical School discussed a study presented at ECTRIMS 2024 that compared the effectiveness and safety profiles of FDA-approved NMOSD therapies with other commonly used treatments. [WATCH TIME: 4 minutes]

Factors Influencing Time Delays in Initiating High-Efficacy Treatment in Multiple Sclerosis: Valentin Krüger, MD

The neurology resident at the University Hospital Frankfurt in Germany talked about a study presented at ECTRIMS 2024 that analyzed time delays in initiating high-efficacy treatments in patients with multiple sclerosis. [WATCH TIME: 4 minutes]

2024 Revisions to McDonald Diagnostic Criteria for Multiple Sclerosis: Peter Calabresi, MD

The codirector of the Precision Medicine MS Center at Johns Hopkins University discussed the new updates to the MS diagnostic criteria presented at the 40th ECTRIMS Congress in Copenhagen. [WATCH TIME: 5 minutes]

Cladribine Data Show Low Overall Disability Accrual in MS, Supporting Early Initiation

Data from the MAGNIFY-MS study suggest that low 24-month PIRA rates across age groups and among those with or without treatment experience.

ENHANCE Data Suggest Safety of Higher-Dose Ublituximab and Shorter Infusion Time

The data showed only a small number of infusion-related reactions among patients with MS transitioning from other disease-modifying therapies.

Remyelinating Effects Seen With Cladribine in Relapsing Multiple Sclerosis

The 2-year study highlighted the potential of cladribine to promote remyelination in highly active relapsing-remitting MS, particularly when early disease control is achieved.

Multi-Ethnic Study Identifies Ancestry-Specific Genetic Variants that Influence Risk of Multiple Sclerosis

A large-scale study presented at ECTRIMS 2024, conducted by the Alliance for Research in Hispanic MS Consortium, identified ancestry-specific genetic factors that influence the risk of developing multiple sclerosis.

Early Monoclonal Antibody Therapy Reduces Long-Term Disability in Pediatric Multiple Sclerosis

Based on findings from the study, investigators stressed the need for better streamlined access to high-efficacy therapies for pediatric patients with onset multiple sclerosis.

Thought Process and Promise Behind Targeting mTOR Pathway for Pediatric Epileptic Encephalopathies: Ghayda Mirzaa, MD

The principal investigator at Seattle Children’s Research Institute provided commentary on the therapeutic potential and hypothesis behind targeting mTOR pathway hyperactivation using pharmacological inhibitors. [WATCH TIME: 3 minutes]

Exposing Young Neurologists to Research Pathways Provided by the NIA, NINDS, VA, and DOD: Claire Henchcliffe, MD, DPhil, FANA; Ali Ezzati, MD

A pair of neurologists from the University of California, Irvine, provided commentary on the ways to help young investigators find their footing in research settings, and exposing them to opportunities major governmental agencies can provide. [WATCH TIME: 4 minutes]

Teaching Neurology Amid an Ever-Changing Field: Galina Gheihman, MD

Critical Values and Characteristics in a Successful Neurology Educator: Galina Gheihman, MD; Roy E. Strowd, MD

Utilizing Global Proteomics and Biomarker Research to Advance Alzheimer Precision Medicine: Fiona Elwood, PhD

The disease area stronghold leader in neurodegeneration at Johnson & Johnson provided insight on the importance of the Global Neurodegeneration Proteomics Consortium, illustrated in several presentations at the recently concluded AAIC 2024. [WATCH TIME: 7 minutes]

Understanding the Connection Between Alzheimer Disease Plasma Biomarkers and Gait Dysfunction: Arjun Masurkar, MD, PhD; Waijha Ahmed, MD

A group of clinician researchers at NYU Langone provided insight on a study presented at AAIC 2024 looking at the correlations between quantitative gait measures and Alzheimer disease biomarkers. [WATCH TIME: 4 minutes]

Overviewing Encouraging Early-Stage Data on Mivelsiran, RNA Therapeutic for Alzheimer Disease: Sharon Cohen, MD, FRCPC

The medical director of the Toronto Memory Program at the University of Toronto provided an in-depth overview of results from an ongoing phase 1 study assessing mivelsiran as a treatment for patients with early-stage Alzheimer disease. [WATCH TIME: 8 minutes]

Therapeutic Potential of Combination Strategies to Treat Alzheimer Disease: Lloyd Tran, PhD

The chairman and chief executive officer at Biomed discussed the additive benefits of combination therapy for Alzheimer disease, providing context on the strengths of different drugs and how it might lead to a more precision medicine approach. [WATCH TIME: 6 minutes]

Utility of Digital Twin AI-Generated Models to Improve Patient Selection in Alzheimer Trials

Steve Herne, chief commercial officer at Unlearn, provided context on a recently conducted study assessing the company’s digital twin methodology AI tool to enhance the statistical certainty of Alzheimer trials.

Episode 122: RNA Therapeutics, Mivelsiran, and Treating Alzheimer Disease

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Sharon Cohen, MD. [LISTEN TIME: 20 minutes]

Expanding the Potential to Treat Alzheimer Disease With RNA Therapeutics: Sharon Cohen, MD, FRCPC

The medical director of the Toronto Memory Program at the University of Toronto gave clinical perspective on the promise of mivelsiran, an investigational RNA interference therapeutic, and the idea behind using RNA therapies to treat Alzheimer disease. [WATCH TIME: 5 minutes]

Exploring Genetic Variants and Global Challenges in Alzheimer Disease Research: Jeffery M. Vance, MD, PhD

The professor of human genetics at the University of Miami discussed the significance of various genetic factors in Alzheimer risk and highlighted ongoing research, therapeutic challenges as well as the need for global collaboration. [WATCH TIME: 10 minutes]

NeuroVoices: Anthony Caggiano, MD, PhD, on Therapeutic Progress of Alzheimer Agent CT1812

The chief medical officer and head of Research & Development at Cognition Therapeutics discussed data from the phase 2 proof-of-concept SHINE study assessing CT1812, a small molecule oligomer antagonist, in early-stage Alzheimer disease.

Expanding the Alzheimer Disease Sequencing Project for Diverse Therapeutic Targets: Jeffery M. Vance, MD, PhD

The professor of human genetics at the University of Miami talked about the Alzheimer's Disease Sequencing Project which aims to provide diverse genetic data to identify therapeutic targets for Alzheimer disease. [WATCH TIME: 10 minutes]

Proof of Concept Behind Neuroprotective Agent NA-831 and Lecanemab for Alzheimer Disease: Lloyd Tran, PhD

The chairman and chief executive officer at Biomed provided insight on the hypothesis behind a new phase 3 study assessing NA-831, an agent with neurogenesis effects, with lecanemab, a previously approved drug for Alzheimer disease. [WATCH TIME: 7 minutes]